These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37066834)

  • 21. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
    Huang Z; Zhou P; Li S; Li K
    Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.
    Shao LJ; Wang YJ; Yin SS; Jiang BB; Liu YH; Wang JC; Yang W; Wu W; Yan K
    Ultrasound Med Biol; 2024 Apr; 50(4):502-508. PubMed ID: 38246805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
    Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
    Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
    Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
    Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study.
    Lee S; Kim KW; Jeong WK; Jeong SY; Hwang JA; Choi JS; Lee SG; Joh JW
    Ann Surg Oncol; 2021 Oct; 28(11):6782-6789. PubMed ID: 33751296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.
    Wen R; Huang W; Song R; Qin L; Wu Y; Peng Y; Huang X; He Y; Yang H
    BMC Med Imaging; 2023 Sep; 23(1):122. PubMed ID: 37697248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.
    Li F; Li Q; Liu Y; Han J; Zheng W; Huang Y; Zheng X; Cao L; Zhou JH
    Eur Radiol; 2020 Jan; 30(1):461-470. PubMed ID: 31297632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LI-RADS Classification and Outcomes of Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.
    Tachibana Y; Takaji R; Maruno M; Honda K; Endo M; Murakami K; Asayama Y
    Cancer Diagn Progn; 2022; 2(4):471-481. PubMed ID: 35813008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017.
    Zeng D; Xu M; Liang JY; Cheng MQ; Huang H; Pan JM; Huang Y; Tong WJ; Xie XY; Lu MD; Kuang M; Chen LD; Hu HT; Wang W
    Radiol Med; 2022 Jan; 127(1):1-10. PubMed ID: 34665430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 39. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic Contrast-Enhanced Ultrasonography Combined With LR-M Classification Criteria for Differentiating Malignant Liver Nodules at High Risk for Hepatocellular Carcinoma.
    Qiu S; Ding J; Wang Y; Zhou H; Zhao L; Zhao L; Zhou Y; Fu Y; Jing X
    Ultrasound Med Biol; 2024 Jul; 50(7):1028-1033. PubMed ID: 38632025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.